Kadmon Holdings LLC Stock News

French pharmaceutical major Sanofi SA said Wednesday that it has entered into a definitive agreement to acquire U.S.-based biopharmaceutical company Kadmon Holdings Inc.

French drugmaker Sanofi SA has agreed to buy U.S. biopharmaceutical company Kadmon Holdings Inc in a $1.9 billion deal, the companies said on Wednesday.

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least tw

NEW YORK, NY / ACCESSWIRE / August 19, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced that REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets is now commercially available for shipme

Penny stocks to buy according to analysts with price targets up to 300% right now. The post 5 Penny Stocks Analysts Say To Buy With Targets Up To 300% appeared first on Penny Stocks to Buy, Picks, New

Investors need to pay close attention to Kadmon Holdings (KDMN) stock based on the movements in the options market lately.

Kadmon Holdings, Inc. (KDMN) delivered earnings and revenue surprises of 0.00% and -42.06%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021. "The re

Despite an approval, Kadmon hasn't done as well as it should. The criminal pasts of its founders have been used as a way to keep it down.

Analysts say these are penny stocks to buy. Do you agree?

Friday afternoon, the FDA approved Kadmon Holdings Inc's (NASDAQ: KDMN) REZUROCK to treat chronic graft-versus-host disease (cGVHD), a serious complication of transplant procedures. Formerly known

Kadmon Holdings Inc. said Friday that Rezurock, its treatment of chronic graft-versus-host disease (cGVHD) in adjusts and pediatric patients older than 12 was approved by the Food and Drug Administrat

- REZUROCK is approved for the treatment of adult and pediatric patients 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy - - Kadmon to Host Conference Call

NEW YORK, June 2, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Kadmon Holdings, Inc. (NASDAQ: KDMN) between October 1, 2020 and

Los Angeles, California--(Newsfile Corp. - June 2, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Kadmon Holdings, Inc.